Literature DB >> 19929941

Prognostic factors for cure following treatment of onychomycosis.

B Sigurgeirsson1.   

Abstract

OBJECTIVE: To examine if host baseline factors and week 24 mycology results are associated with mycological and clinical cure in patients with onychomycosis treated with oral terbinafine.
DESIGN: Open pilot study to determine prognostic factors in the treatment of onychomycosis.
SETTING: Outpatient dermatology clinic. PATIENTS: A total of 199 patients from the Icelandic arm of a trial comparing continuous terbinafine with intermittent terbinafine in onychomycosis were recruited for additional observation. MAIN OUTCOME MEASURES: Mycological, clinical and complete cure of the target toenail 72 weeks after treatment was initiated.
RESULTS: Patients with matrix involvement or slow nail growth were less likely to reach mycological, clinical and complete cure. Lateral involvement affected complete and mycological cure rates negatively. Patients with a dermatophytoma were less likely to reach mycological cure. Patients with a history of prior infection, men and older patients were less likely to reach clinical cure. Positive culture at 24 weeks affected mycological and clinical cure at 72 weeks negatively. LIMITATIONS: Only patients treated with terbinafine were considered.
CONCLUSIONS: Several host-related factors at baseline and positive culture at 24 weeks had negative effects on cure of onychomycosis 72 weeks after treatment was initiated. This finding merits a large study on prognostic outcome factors in onychomycosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19929941     DOI: 10.1111/j.1468-3083.2009.03487.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  11 in total

Review 1.  Variability in Systemic Treatment Efficacy for Onychomycosis: Information That Clinical Studies Do Not Impart to the Office Dermatologist.

Authors:  Avner Shemer; Ralph Daniel; Dimitris Rigopoulos; Renata Farhi; Meir Babaev
Journal:  Skin Appendage Disord       Date:  2017-10-26

Review 2.  A Paradigm Shift in the Treatment and Management of Onychomycosis.

Authors:  Aditya K Gupta; Maanasa Venkataraman; Helen J Renaud; Richard Summerbell; Neil H Shear; Vincent Piguet
Journal:  Skin Appendage Disord       Date:  2021-05-11

3.  Onychomycosis of Toenails and Post-hoc Analyses with Efinaconazole 10% Solution Once-daily Treatment: Impact of Disease Severity and Other Concomitant Associated Factors on Selection of Therapy and Therapeutic Outcomes.

Authors:  James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2016-02

4.  Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study.

Authors:  Shinichi Watanabe; Ichiro Tsubouchi; Akihiro Okubo
Journal:  J Dermatol       Date:  2018-08-29       Impact factor: 4.005

Review 5.  Dermatophytomas: Clinical Overview and Treatment.

Authors:  Aditya K Gupta; Tong Wang; Elizabeth A Cooper
Journal:  J Fungi (Basel)       Date:  2022-07-19

6.  Efinaconazole 10% Topical Solution: Case Review of Onychomycosis Patients Who Were Completely Cured at Week 24.

Authors:  Boni E Elewski; Antonella Tosti; Tina Lin
Journal:  Skin Appendage Disord       Date:  2017-08-10

7.  Efinaconazole Topical Solution, 10%, for the Treatment of Mild and Moderate Toenail Onychomycosis.

Authors:  David A Rodriguez
Journal:  J Clin Aesthet Dermatol       Date:  2015-06

8.  Excellent Response of Dermatophytoma and Nail Splitting to Nail Plate Debridement Plus Topical Ciclopirox Olamine 1% Solution.

Authors:  Hamed Mohamed Abdo
Journal:  Skin Appendage Disord       Date:  2020-12-09

9.  Natural coniferous resin lacquer in treatment of toenail onychomycosis: an observational study.

Authors:  Pentti Sipponen; Arno Sipponen; Jouni Lohi; Marjo Soini; Riikka Tapanainen; Janne J Jokinen
Journal:  Mycoses       Date:  2012-11-06       Impact factor: 4.377

10.  Onychomycosis: clinical, mycological and in vitro susceptibility testing of isolates of Trichophyton rubrum.

Authors:  Christiane Venske de Almeida Azambuja; Luciana Alves Pimmel; Gabriel Baracy Klafke; Melissa Orzechowski Xavier
Journal:  An Bras Dermatol       Date:  2014 Jul-Aug       Impact factor: 1.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.